Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Peptide Process CMCPeptide Process CMC
Not Confirmed
Not Confirmed
28-30 August, 2025
Not Confirmed
Not Confirmed
01-03 September, 2025
Process DevelopmentProcess Development
Not Confirmed
Not Confirmed
01 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Peptide Process CMCPeptide Process CMC
Industry Trade Show
Not Confirmed
28-30 August, 2025
Industry Trade Show
Not Confirmed
01-03 September, 2025
Process DevelopmentProcess Development
Industry Trade Show
Not Confirmed
01 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
27 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/avidity-biosciences-to-participate-in-upcoming-investor-conferences-302538395.html
09 Aug 2025
// REUTERS
https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-weighs-deal-biotech-avidity-biosciences-ft-reports-2025-08-06/
28 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/avidity-biosciences-announces-completion-of-enrollment-for-harbor-the-first-global-phase-3-trial-of-delpacibart-etedesiran-del-desiran-for-treatment-of-dm1-and-provides-guidance-on-regulatory-submission-302514520.html
23 Jul 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/avidity-biosciences-receives-fda-breakthrough-therapy-designation-for-delpacibart-zotadirsen-del-zota-for-the-treatment-of-dmd-in-people-with-mutations-amenable-to-exon-44-skipping-302511334.html
11 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/avidity-biosciences-to-present-topline-data-from-phase-12-fortitude-trial-of-del-brax-in-people-living-with-facioscapulohumeral-muscular-dystrophy-at-32nd-annual-fshd-society-international-research-congress-302478339.html
09 Jun 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/avidity-biosciences-announces-positive-topline-phase-12-fortitude-data-demonstrating-consistent-improvement-across-multiple-functional-measures-compared-to-placebo-in-del-brax-treated-fshd-participants-302476040.html
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE